FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394516> ?p ?o ?g. }

• W4308394516 abstract "<h3>Background</h3> Innate immune modulators such as STING agonists have become attractive approaches to improve the efficacy of Immune Checkpoint Inhibitors (ICI) due to their ability to turn cold tumors hot. Owing to the modest clinical efficacy of STING agonists, there is a need for other approaches for activating the cGAS-STING pathway for cancer immunotherapy. One such approach is through the inhibition of the enzyme ENPP1, a negative regulator of the STING pathway which directly hydrolyses 2′3′- cGAMP. <i>ENPP1</i> is overexpressed in several tumor cells like human astrocyte tumors and TNBC cells like 4T1 and MDA-MB-231, and plays a key role in tumor progression and block T cell infiltration in breast and lung cancer patients. ENPP1 not only abolishes the cGAS-STING mediated immune activation but also produces adenosine, an immune suppressor which promotes cell migration. AVA-NP-695 is a highly potent orally available ENPP1 inhibitor being developed for cancer immunotherapy. <h3>Methods</h3> The inhibition potency of AVA-NP-695 was confirmed by enzymatic assays using various substrate like p-Nitrophenyl-5′-TMP, cGAMP and ATP. The efficacy of AVA-NP-695 was depicted in 4T1 Tumor bearing BALB/c mice as monotherapy and in combination with anti-PD-L1, Olaparib and Paclitaxel. Efficacy of AVA-NP-695 in combination with radiation (6.2Gy X 4) was also evaluated in ENPP1 overexpressing ANV5 tumors. <h3>Results</h3> Herein, we demonstrate that AVA-NP-695, a selective and potent ENPP1 inhibitor showed no adverse effect at 1000mg/kg BID in 7 Day repeated dose in BALB/C mice, thereby demonstrating an excellent therapeutic window?. Results from in vivo studies have shown superior tumor growth inhibition (TGI) and impact on tumor metastasis by AVA-NP-695 (6mg/kg BID) compared to Olaparib and Anti-PD1 in a syngeneic 4T1 breast cancer mouse model. Subsequently, combination of AVA-NP-695 with Anti-PDL1, Olaparib and Paclitaxel and demonstrated encouraging combinatorial efficacy of AVA-NP-695 along with Paclitaxel. Monotherapeutic arm for Paclitaxel and AVA-NP-695 depicted 40% and 44% TGI respectively, however their combined treatment resulted in ~60% TGI. Additionally, the AVA-NP-695 treatment alone showed 50% enhanced mean survival time followed by 68%, 68% and 72% when given in combination with anti-PD-L1, Olaparib and Paclitaxel respectively. Finally, AVA-NP-695 showed complete tumor ablation of ANV5 ENPP1 overexpressed tumors when given in combination with radiation. Combination group showed significantly delayed recurrence compared to only radiotherapy. <h3>Conclusions</h3> The potent anti-tumor efficacy of AVA-NP-695 both as monotherapy and combination along with its safety profile provides a strong rationale for the therapeutic potential of AVA-NP-695 against solids tumors, particularly breast cancer." @default.
• W4308394516 created "2022-11-11" @default.
• W4308394516 creator A5009137011 @default.
• W4308394516 creator A5015926248 @default.
• W4308394516 creator A5049544741 @default.
• W4308394516 creator A5055347652 @default.
• W4308394516 creator A5073188285 @default.
• W4308394516 date "2022-11-01" @default.
• W4308394516 modified "2023-10-16" @default.
• W4308394516 title "1335 AVA-NP-695 potently and selectively inhibits ENPP1 to activate STING pathway and abrogate tumor metastasis in 4T1 breast cancer syngeneic mouse model" @default.
• W4308394516 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1335" @default.
• W4308394516 hasPublicationYear "2022" @default.
• W4308394516 type Work @default.
• W4308394516 citedByCount "0" @default.
• W4308394516 crossrefType "proceedings-article" @default.
• W4308394516 hasAuthorship W4308394516A5009137011 @default.
• W4308394516 hasAuthorship W4308394516A5015926248 @default.
• W4308394516 hasAuthorship W4308394516A5049544741 @default.
• W4308394516 hasAuthorship W4308394516A5055347652 @default.
• W4308394516 hasAuthorship W4308394516A5073188285 @default.
• W4308394516 hasBestOaLocation W43083945161 @default.
• W4308394516 hasConcept C121608353 @default.
• W4308394516 hasConcept C126322002 @default.
• W4308394516 hasConcept C127413603 @default.
• W4308394516 hasConcept C146978453 @default.
• W4308394516 hasConcept C185592680 @default.
• W4308394516 hasConcept C203014093 @default.
• W4308394516 hasConcept C2777701055 @default.
• W4308394516 hasConcept C2779013556 @default.
• W4308394516 hasConcept C2779300339 @default.
• W4308394516 hasConcept C2780674031 @default.
• W4308394516 hasConcept C502942594 @default.
• W4308394516 hasConcept C71924100 @default.
• W4308394516 hasConcept C8891405 @default.
• W4308394516 hasConcept C96232424 @default.
• W4308394516 hasConcept C98274493 @default.
• W4308394516 hasConceptScore W4308394516C121608353 @default.
• W4308394516 hasConceptScore W4308394516C126322002 @default.
• W4308394516 hasConceptScore W4308394516C127413603 @default.
• W4308394516 hasConceptScore W4308394516C146978453 @default.
• W4308394516 hasConceptScore W4308394516C185592680 @default.
• W4308394516 hasConceptScore W4308394516C203014093 @default.
• W4308394516 hasConceptScore W4308394516C2777701055 @default.
• W4308394516 hasConceptScore W4308394516C2779013556 @default.
• W4308394516 hasConceptScore W4308394516C2779300339 @default.
• W4308394516 hasConceptScore W4308394516C2780674031 @default.
• W4308394516 hasConceptScore W4308394516C502942594 @default.
• W4308394516 hasConceptScore W4308394516C71924100 @default.
• W4308394516 hasConceptScore W4308394516C8891405 @default.
• W4308394516 hasConceptScore W4308394516C96232424 @default.
• W4308394516 hasConceptScore W4308394516C98274493 @default.
• W4308394516 hasLocation W43083945161 @default.
• W4308394516 hasOpenAccess W4308394516 @default.
• W4308394516 hasPrimaryLocation W43083945161 @default.
• W4308394516 hasRelatedWork W2154708791 @default.
• W4308394516 hasRelatedWork W2763883091 @default.
• W4308394516 hasRelatedWork W2937326325 @default.
• W4308394516 hasRelatedWork W3180780036 @default.
• W4308394516 hasRelatedWork W4220665865 @default.
• W4308394516 hasRelatedWork W4283771460 @default.
• W4308394516 hasRelatedWork W4291367166 @default.
• W4308394516 hasRelatedWork W4304116770 @default.
• W4308394516 hasRelatedWork W4360983034 @default.
• W4308394516 hasRelatedWork W4364321816 @default.
• W4308394516 isParatext "false" @default.
• W4308394516 isRetracted "false" @default.
• W4308394516 workType "article" @default.